138 related articles for article (PubMed ID: 27468083)
1. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.
de Maleissye MF; Nicolas G; Saiag P
N Engl J Med; 2016 Jul; 375(3):296-7. PubMed ID: 27468083
[No Abstract] [Full Text] [Related]
2. Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
Kobayashi Y; Iijima K; Kondo Y; Yamamoto K; Sekijima Y
Acta Neurol Belg; 2024 Jun; 124(3):1063-1065. PubMed ID: 38010574
[No Abstract] [Full Text] [Related]
3. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
Cho HS; Lee KY; Hu CJ; Chung CC
Neurol India; 2018; 66(2):509-511. PubMed ID: 29547174
[No Abstract] [Full Text] [Related]
4. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report.
Basilious A; Lloyd JC
Can J Ophthalmol; 2016 Feb; 51(1):e4-6. PubMed ID: 26874174
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for melanoma- safety profile and future trends.
Daud A; Nandoskar P
Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
[No Abstract] [Full Text] [Related]
6. Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis: Coincidence or contributory?
Lee AYS; Hannaford A; Vucic S; Berglund LJ
Ann Allergy Asthma Immunol; 2022 Jan; 128(1):105-106. PubMed ID: 34481048
[No Abstract] [Full Text] [Related]
7. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma.
Alnahhas I; Wong J
Muscle Nerve; 2017 Jun; 55(6):E25-E26. PubMed ID: 27935080
[No Abstract] [Full Text] [Related]
8. Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma.
Anthoney DA; Bone I; Evans TR
Ann Oncol; 2000 Sep; 11(9):1197-200. PubMed ID: 11061619
[TBL] [Abstract][Full Text] [Related]
9. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.
Chan MM; Kefford RF; Carlino M; Clements A; Manolios N
J Immunother; 2015 Jan; 38(1):37-9. PubMed ID: 25415286
[TBL] [Abstract][Full Text] [Related]
10. Could knee inflammatory synovitis be induced by pembrolizumab?
Mahmoud F; Wilkinson JT; Gizinski A; Viswamitra S; Gokden N; Vander Schilden J
J Oncol Pharm Pract; 2018 Jul; 24(5):389-392. PubMed ID: 28355971
[TBL] [Abstract][Full Text] [Related]
11. Prominent cauda equina involvement in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Matsumoto H; Hanajima R; Terao Y; Yugeta A; Hamada M; Shirota Y; Ohminami S; Nakatani-Enomoto S; Tsuji S; Ugawa Y
J Neurol Sci; 2010 Mar; 290(1-2):112-4. PubMed ID: 19900685
[TBL] [Abstract][Full Text] [Related]
12. Steroid-induced inflammatory neuropathy in a patient on tumor necrosis factor-α antagonist therapy.
Wong SL; Rajabally YA
J Clin Neuromuscul Dis; 2010 Dec; 12(2):88-90. PubMed ID: 21386777
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.
Fargeot G; Dupel-Pottier C; Stephant M; Lazarovici J; Thomas L; Mouthon-Reignier C; Riad B; Carde P; Berzero G; Tafani C; Nicolas W; Viala K; Maisonobe T; Lenglet T; Wang A; Magy L; Bihan K; Gaspar N; Adams D; Echaniz-Laguna A; Cauquil C; Psimaras D
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):786-788. PubMed ID: 32327451
[No Abstract] [Full Text] [Related]
14. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
15. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2008 Aug; 38(2):1036-45. PubMed ID: 18642356
[TBL] [Abstract][Full Text] [Related]
16. Duration of the distal compound muscle action potential for diagnosis of chronic inflammatory demyelinating polyneuropathy: effects of low-cut filters.
Isose S; Misawa S; Sonoo M; Shimuzu T; Oishi C; Shibuya K; Nasu S; Sekiguchi Y; Mitsuma S; Beppu M; Omori S; Komori T; Kokubun N; Inaba A; Hirashima F; Kuwabara S;
J Clin Neurophysiol; 2014 Oct; 31(5):441-3. PubMed ID: 25271683
[TBL] [Abstract][Full Text] [Related]
17. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
Carlos G; Anforth R; Chou S; Clements A; Fernandez-Peñas P
Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
Sullivan RJ; Flaherty KT
Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?
Brannagan TH; Patterson SK
Expert Rev Clin Immunol; 2010 May; 6(3):319-21. PubMed ID: 20441416
[No Abstract] [Full Text] [Related]
20. Chronic inflammatory demyelinating polyneuropathy in a patient with hyperIgEaemia.
Kimura A; Yoshino H; Yuasa T
J Neurol Sci; 2005 Apr; 231(1-2):89-93. PubMed ID: 15792827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
